MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$69,707K
EPS
-$0.98
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Research and development
54,515 36,957* 60,635 49,762
General and administrative
15,509 9,370* 10,799 10,936
Total operating expenses
70,024 46,326 71,434 60,698
Operating loss
-70,024 -46,326* -71,434 -60,698
Interest expense
2,269 -604* 3,198 2,037
Other income, net
3,208 6,124* 4,053 6,779
Loss before income tax
-69,085 -39,598* -70,579 -55,956
Income tax expense
622 296* 115 95
Net loss
-69,707 -39,894 -70,694 -56,051
Of which net loss attributable to noncontrolling interests shareholders
----831
Of which net loss attributable to controlling interests shareholders
-69,707 -39,894 -69,729 -55,220
Basic EPS
-0.98 -0.598 -1.1 -0.87
Diluted EPS
-0.98 -0.598 -1.1 -0.87
Basic Average Shares
71,273,650 66,738,955 63,369,984 63,282,728
Diluted Average Shares
71,273,650 66,738,955 63,369,984 63,282,728
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Of which net lossattributable to controlling...-$69,707K Net loss-$69,707K Loss before incometax-$69,085K Income tax expense$622K Other income, net$3,208K Operating loss-$70,024K Interest expense$2,269K Total operatingexpenses$70,024K Research and development$54,515K General andadministrative$15,509K

MoonLake Immunotherapeutics (MLTX)

MoonLake Immunotherapeutics (MLTX)